Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 68

1.

EANO-EURACAN clinical practice guideline for diagnosis, treatment, and follow-up of post-pubertal and adult patients with medulloblastoma.

Franceschi E, Hofer S, Brandes AA, Frappaz D, Kortmann RD, Bromberg J, Dangouloff-Ros V, Boddaert N, Hattingen E, Wiestler B, Clifford SC, Figarella-Branger D, Giangaspero F, Haberler C, Pietsch T, Pajtler KW, Pfister SM, Guzman R, Stummer W, Combs SE, Seidel C, Beier D, McCabe MG, Grotzer M, Laigle-Donadey F, Stücklin ASG, Idbaih A, Preusser M, van den Bent M, Weller M, Hau P.

Lancet Oncol. 2019 Dec;20(12):e715-e728. doi: 10.1016/S1470-2045(19)30669-2. Review.

PMID:
31797797
2.

Glioblastoma in the elderly.

Laigle-Donadey F.

Geriatr Psychol Neuropsychiatr Vieil. 2019 Jun 1;17(2):173-178. doi: 10.1684/pnv.2019.0799.

PMID:
30998187
3.

Safety and Feasibility of Repeated and Transient Blood-Brain Barrier Disruption by Pulsed Ultrasound in Patients with Recurrent Glioblastoma.

Idbaih A, Canney M, Belin L, Desseaux C, Vignot A, Bouchoux G, Asquier N, Law-Ye B, Leclercq D, Bissery A, De Rycke Y, Trosch C, Capelle L, Sanson M, Hoang-Xuan K, Dehais C, Houillier C, Laigle-Donadey F, Mathon B, André A, Lafon C, Chapelon JY, Delattre JY, Carpentier A.

Clin Cancer Res. 2019 Jul 1;25(13):3793-3801. doi: 10.1158/1078-0432.CCR-18-3643. Epub 2019 Mar 19.

PMID:
30890548
4.

[The GLITRAD (Adult Brainstem Gliomas) network: A national multidisciplinary group dedicated to brainstem gliomas in adults].

Laigle-Donadey F, Loiseau H; au nom du groupe GLITRAD du réseau TUCERA de l’ANOCEF.

Bull Cancer. 2017 Jun;104(6):593-595. doi: 10.1016/j.bulcan.2017.03.007. Epub 2017 Apr 17. French. No abstract available.

PMID:
28427714
5.

Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma.

Perry JR, Laperriere N, O'Callaghan CJ, Brandes AA, Menten J, Phillips C, Fay M, Nishikawa R, Cairncross JG, Roa W, Osoba D, Rossiter JP, Sahgal A, Hirte H, Laigle-Donadey F, Franceschi E, Chinot O, Golfinopoulos V, Fariselli L, Wick A, Feuvret L, Back M, Tills M, Winch C, Baumert BG, Wick W, Ding K, Mason WP; Trial Investigators.

N Engl J Med. 2017 Mar 16;376(11):1027-1037. doi: 10.1056/NEJMoa1611977.

6.

Intracerebral injection of CpG oligonucleotide for patients with de novo glioblastoma-A phase II multicentric, randomised study.

Ursu R, Carpentier A, Metellus P, Lubrano V, Laigle-Donadey F, Capelle L, Guyotat J, Langlois O, Bauchet L, Desseaux K, Tibi A, Chinot O, Lambert J, Carpentier AF.

Eur J Cancer. 2017 Mar;73:30-37. doi: 10.1016/j.ejca.2016.12.003. Epub 2017 Jan 28.

PMID:
28142059
7.

[Adolescent and Young Adults (AYAS) brain tumor national Web conference. On behalf of ANOCEF, GO-AJA and SFCE societies].

Frappaz D, Sunyach MP, Le Rhun E, Blonski M, Laurence V, Bonneville Levard A, Loiseau H, Meyronnet D, Callies A, Laigle-Donadey F, Faure Conter C; au nom de l’ANOCEF, GO-AJA, de la SFCE.

Bull Cancer. 2016 Dec;103(12):1050-1056. doi: 10.1016/j.bulcan.2016.10.010. Epub 2016 Nov 17. French.

PMID:
27866682
8.

The multidimensional burden of informal caregivers in primary malignant brain tumor.

Bayen E, Laigle-Donadey F, Prouté M, Hoang-Xuan K, Joël ME, Delattre JY.

Support Care Cancer. 2017 Jan;25(1):245-253. Epub 2016 Sep 13.

PMID:
27624465
9.

Role of irradiation for patients over 80 years old with glioblastoma: a retrospective cohort study.

Bracci S, Laigle-Donadey F, Hitchcock K, Duran-Peña A, Navarro S, Chevalier A, Jacob J, Troussier I, Delattre JY, Mazeron JJ, Hoang-Xuan K, Feuvret L.

J Neurooncol. 2016 Sep;129(2):347-53. doi: 10.1007/s11060-016-2182-1. Epub 2016 Jun 16.

PMID:
27311728
10.

Diagnostic and prognostic value of preoperative combined GFAP, IGFBP-2, and YKL-40 plasma levels in patients with glioblastoma.

Gállego Pérez-Larraya J, Paris S, Idbaih A, Dehais C, Laigle-Donadey F, Navarro S, Capelle L, Mokhtari K, Marie Y, Sanson M, Hoang-Xuan K, Delattre JY, Mallet A.

Cancer. 2014 Dec 15;120(24):3972-80. doi: 10.1002/cncr.28949. Epub 2014 Aug 19.

11.

Temozolomide after radiotherapy in recurrent "low grade" diffuse brainstem glioma in adults.

Reyes-Botero G, Laigle-Donadey F, Mokhtari K, Martin-Duverneuil N, Delattre JY.

J Neurooncol. 2014 Dec;120(3):581-6. doi: 10.1007/s11060-014-1589-9. Epub 2014 Aug 20. Erratum in: J Neurooncol. 2014 Dec;120(3):587.

PMID:
25139026
12.

Clinical value of chromosome arms 19q and 11p losses in low-grade gliomas.

Alentorn A, van Thuijl HF, Marie Y, Alshehhi H, Carpentier C, Boisselier B, Laigle-Donadey F, Mokhtari K, Scheinin I, Wesseling P, Ylstra B, Capelle L, Hoang-Xuan K, Sanson M, Delattre JY, Reijneveld JC, Idbaih A.

Neuro Oncol. 2014 Mar;16(3):400-8. doi: 10.1093/neuonc/not227. Epub 2013 Dec 12.

13.

Molecular analysis of diffuse intrinsic brainstem gliomas in adults.

Reyes-Botero G, Giry M, Mokhtari K, Labussière M, Idbaih A, Delattre JY, Laigle-Donadey F, Sanson M.

J Neurooncol. 2014 Jan;116(2):405-11. doi: 10.1007/s11060-013-1312-2. Epub 2013 Nov 17.

PMID:
24242757
14.

EORTC 26083 phase I/II trial of dasatinib in combination with CCNU in patients with recurrent glioblastoma.

Franceschi E, Stupp R, van den Bent MJ, van Herpen C, Laigle Donadey F, Gorlia T, Hegi M, Lhermitte B, Strauss LC, Allgeier A, Lacombe D, Brandes AA.

Neuro Oncol. 2012 Dec;14(12):1503-10. doi: 10.1093/neuonc/nos256. Epub 2012 Oct 22.

15.

Adult brainstem gliomas.

Reyes-Botero G, Mokhtari K, Martin-Duverneuil N, Delattre JY, Laigle-Donadey F.

Oncologist. 2012;17(3):388-97. doi: 10.1634/theoncologist.2011-0335. Epub 2012 Mar 1. Review.

16.

Brainstem tumors.

Laigle-Donadey F, Doz F, Delattre JY.

Handb Clin Neurol. 2012;105:585-605. doi: 10.1016/B978-0-444-53502-3.00010-0. Review. No abstract available.

PMID:
22230520
17.

[Glioblastoma in the elderly].

Laigle-Donadey F, Delattre JY.

Geriatr Psychol Neuropsychiatr Vieil. 2011 Mar;9(1):101-6. doi: 10.1684/pnv.2010.0251. French.

PMID:
21586383
18.

IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas.

Houillier C, Wang X, Kaloshi G, Mokhtari K, Guillevin R, Laffaire J, Paris S, Boisselier B, Idbaih A, Laigle-Donadey F, Hoang-Xuan K, Sanson M, Delattre JY.

Neurology. 2010 Oct 26;75(17):1560-6. doi: 10.1212/WNL.0b013e3181f96282.

PMID:
20975057
19.

Reappraisal of clinical outcome in adult medulloblastomas with emphasis on patterns of relapse.

Chargari C, Feuvret L, Levy A, Lamproglou I, Assouline A, Hemery C, Ghorbal L, Lopez S, Tep B, G GB, Lang P, Laigle-Donadey F, Cornu P, Mazeron JJ, Simon JM.

Br J Neurosurg. 2010 Aug;24(4):460-7. doi: 10.3109/02688691003739881.

PMID:
20726753
20.

Up-front temozolomide in elderly patients with anaplastic oligodendroglioma and oligoastrocytoma.

Ducray F, del Rio MS, Carpentier C, Psimaras D, Idbaih A, Dehais C, Kaloshi G, Mokhtari K, Taillibert S, Laigle-Donadey F, Omuro A, Sanson M, Delattre JY, Hoang-Xuan K.

J Neurooncol. 2011 Feb;101(3):457-62. doi: 10.1007/s11060-010-0264-z. Epub 2010 Jun 17.

PMID:
20556480
21.

Nitrosourea-based chemotherapy for low grade gliomas failing initial treatment with temozolomide.

Kaloshi G, Sierra del Rio M, Ducray F, Psimaras D, Idbaih A, Laigle-Donadey F, Taillibert S, Houillier C, Dehais C, Omuro A, Sanson M, Delattre JY, Hoang-Xuan K.

J Neurooncol. 2010 Dec;100(3):439-41. doi: 10.1007/s11060-010-0197-6. Epub 2010 May 13.

PMID:
20464625
22.

Intracerebral administration of CpG oligonucleotide for patients with recurrent glioblastoma: a phase II study.

Carpentier A, Metellus P, Ursu R, Zohar S, Lafitte F, Barrié M, Meng Y, Richard M, Parizot C, Laigle-Donadey F, Gorochov G, Psimaras D, Sanson M, Tibi A, Chinot O, Carpentier AF.

Neuro Oncol. 2010 Apr;12(4):401-8. doi: 10.1093/neuonc/nop047. Epub 2010 Jan 25.

23.

Chromosome 9p and 10q losses predict unfavorable outcome in low-grade gliomas.

Houillier C, Mokhtari K, Carpentier C, Crinière E, Marie Y, Rousseau A, Kaloshi G, Dehais C, Laffaire J, Laigle-Donadey F, Hoang-Xuan K, Sanson M, Delattre JY.

Neuro Oncol. 2010 Jan;12(1):2-6. doi: 10.1093/neuonc/nop002. Epub 2009 Oct 15.

24.

Up-front temozolomide in elderly patients with glioblastoma.

Laigle-Donadey F, Figarella-Branger D, Chinot O, Taillandier L, Cartalat-Carel S, Honnorat J, Kaloshi G, Delattre JY, Sanson M.

J Neurooncol. 2010 Aug;99(1):89-94. doi: 10.1007/s11060-009-0110-3. Epub 2010 Jan 8.

PMID:
20058048
25.

Supratentorial low-grade gliomas in older patients.

Kaloshi G, Psimaras D, Mokhtari K, Dehais C, Houillier C, Marie Y, Laigle-Donadey F, Taillibert S, Guillevin R, Martin-Duverneuil N, Sanson M, Hoang-Xuan K, Delattre JY.

Neurology. 2009 Dec 15;73(24):2093-8. doi: 10.1212/WNL.0b013e3181c6781e. Epub 2009 Nov 11.

PMID:
19907009
26.

Gray matter involvement predicts chemosensitivity and prognosis in gliomatosis cerebri.

Kaloshi G, Guillevin R, Martin-Duverneuil N, Laigle-Donadey F, Psimaras D, Marie Y, Mokhtari K, Hoang-Xuan K, Delattre JY, Sanson M.

Neurology. 2009 Aug 11;73(6):445-9. doi: 10.1212/WNL.0b013e3181b163e2.

PMID:
19667319
27.

Bevacizumab and irinotecan for recurrent oligodendroglial tumors.

Taillibert S, Vincent LA, Granger B, Marie Y, Carpentier C, Guillevin R, Bellanger A, Mokhtari K, Rousseau A, Psimaras D, Dehais C, Sierra del Rio M, Meng Y, Laigle-Donadey F, Hoang-Xuan K, Sanson M, Delattre JY.

Neurology. 2009 May 5;72(18):1601-6. doi: 10.1212/WNL.0b013e3181a413be.

PMID:
19414728
28.

[Malignant gliomas in the elderly].

Laigle-Donadey F.

Soins. 2009 Mar;(733):43. French. No abstract available.

PMID:
19366003
29.

[Association of radiotherapy and chemotherapy-targeted therapies in glioblastomas].

Laigle-Donadey F, Dehais C, Mazeron JJ, Sanson M.

Bull Cancer. 2009 Mar;96(3):291-7. doi: 10.1684/bdc.2009.0835. Review. French.

30.

Epidermal growth factor receptor extracellular domain mutations in primary glioblastoma.

Idbaih A, Aimard J, Boisselier B, Marie Y, Paris S, Crinière E, Carvalho Silva R, Laigle-Donadey F, Rousseau A, Mokhtari K, Thillet J, Sanson M, Hoang-Xuan K, Delattre JY.

Neuropathol Appl Neurobiol. 2009 Apr;35(2):208-13. doi: 10.1111/j.1365-2990.2008.00977.x.

PMID:
19284481
31.

Identification of regions correlating MGMT promoter methylation and gene expression in glioblastomas.

Everhard S, Tost J, El Abdalaoui H, Crinière E, Busato F, Marie Y, Gut IG, Sanson M, Mokhtari K, Laigle-Donadey F, Hoang-Xuan K, Delattre JY, Thillet J.

Neuro Oncol. 2009 Aug;11(4):348-56. doi: 10.1215/15228517-2009-001. Epub 2009 Feb 17.

32.

TP53 codon 72 polymorphism is associated with age at onset of glioblastoma.

El Hallani S, Ducray F, Idbaih A, Marie Y, Boisselier B, Colin C, Laigle-Donadey F, Rodéro M, Chinot O, Thillet J, Hoang-Xuan K, Delattre JY, Sanson M.

Neurology. 2009 Jan 27;72(4):332-6. doi: 10.1212/01.wnl.0000341277.74885.ec.

PMID:
19171829
33.

alpha-Internexin expression identifies 1p19q codeleted gliomas.

Ducray F, Crinière E, Idbaih A, Mokhtari K, Marie Y, Paris S, Navarro S, Laigle-Donadey F, Dehais C, Thillet J, Hoang-Xuan K, Delattre JY, Sanson M.

Neurology. 2009 Jan 13;72(2):156-61. doi: 10.1212/01.wnl.0000339055.64476.cb.

PMID:
19139367
34.

Brainstem gliomas in children and adults.

Laigle-Donadey F, Doz F, Delattre JY.

Curr Opin Oncol. 2008 Nov;20(6):662-7. doi: 10.1097/CCO.0b013e32831186e0. Review.

PMID:
18841048
35.

Prognostic significance of imaging contrast enhancement for WHO grade II gliomas.

Pallud J, Capelle L, Taillandier L, Fontaine D, Mandonnet E, Guillevin R, Bauchet L, Peruzzi P, Laigle-Donadey F, Kujas M, Guyotat J, Baron MH, Mokhtari K, Duffau H.

Neuro Oncol. 2009 Apr;11(2):176-82. doi: 10.1215/15228517-2008-066. Epub 2008 Aug 12.

36.

[Gliomas in the elderly].

Laigle-Donadey F, Navarro S, Delattre JY.

Rev Neurol (Paris). 2008 Jun-Jul;164(6-7):542-6. doi: 10.1016/j.neurol.2008.03.013. Epub 2008 May 13. Review. French.

PMID:
18565352
37.

Gene amplification is a poor prognostic factor in anaplastic oligodendrogliomas.

Idbaih A, Crinière E, Marie Y, Rousseau A, Mokhtari K, Kujas M, El Houfi Y, Carpentier C, Paris S, Boisselier B, Laigle-Donadey F, Thillet J, Sanson M, Hoang-Xuan K, Delattre JY.

Neuro Oncol. 2008 Aug;10(4):540-7. doi: 10.1215/15228517-2008-022. Epub 2008 Jun 10.

38.

Complete response after one cycle of temozolomide in an elderly patient with glioblastoma and poor performance status.

Ducray F, Benouaich-Amiel A, Idbaih A, Rousseau A, Laigle-Donadey F, Delattre JY, Sanson M.

J Neurooncol. 2008 Jun;88(2):185-8. doi: 10.1007/s11060-008-9546-0.

PMID:
18317694
39.

Genetic markers predictive of chemosensitivity and outcome in gliomatosis cerebri.

Kaloshi G, Everhard S, Laigle-Donadey F, Marie Y, Navarro S, Mokhtari K, Idbaih A, Ducray F, Thillet J, Hoang-Xuan K, Delattre JY, Sanson M.

Neurology. 2008 Feb 19;70(8):590-5. doi: 10.1212/01.wnl.0000299896.65604.ae.

PMID:
18285534
40.

Influence of MDM2 SNP309 alone or in combination with the TP53 R72P polymorphism in oligodendroglial tumors.

Idbaih A, Boisselier B, Marie Y, Sanson M, El Hallani S, Crinière E, Fourtassi M, Paris S, Carpentier C, Rousseau A, Mokhtari K, Combadière C, Laigle-Donadey F, Hoang-Xuan K, Delattre JY.

Brain Res. 2008 Mar 10;1198:16-20. doi: 10.1016/j.brainres.2008.01.027. Epub 2008 Jan 18.

PMID:
18262501
41.

TP53 codon 72 polymorphism, p53 expression, and 1p/19q status in oligodendroglial tumors.

Idbaih A, Boisselier B, Marie Y, El Hallani S, Sanson M, Crinière E, Rodero M, Carpentier C, Paris S, Laigle-Donadey F, Ducray F, Hoang-Xuan K, Delattre JY.

Cancer Genet Cytogenet. 2007 Sep;177(2):103-7.

PMID:
17854663
42.

Tumor genomic profiling and TP53 germline mutation analysis of first-degree relative familial gliomas.

Idbaih A, Boisselier B, Sanson M, Crinière E, Liva S, Marie Y, Carpentier C, Paris S, Laigle-Donadey F, Mokhtari K, Kujas M, Hoang-Xuan K, Delattre O, Delattre JY.

Cancer Genet Cytogenet. 2007 Jul 15;176(2):121-6.

PMID:
17656254
43.

No association of MDM2 SNP309 with risk of glioblastoma and prognosis.

El Hallani S, Marie Y, Idbaih A, Rodero M, Boisselier B, Laigle-Donadey F, Ducray F, Delattre JY, Sanson M.

J Neurooncol. 2007 Dec;85(3):241-4. Epub 2007 Jun 14.

PMID:
17568997
44.

Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome.

Kaloshi G, Benouaich-Amiel A, Diakite F, Taillibert S, Lejeune J, Laigle-Donadey F, Renard MA, Iraqi W, Idbaih A, Paris S, Capelle L, Duffau H, Cornu P, Simon JM, Mokhtari K, Polivka M, Omuro A, Carpentier A, Sanson M, Delattre JY, Hoang-Xuan K.

Neurology. 2007 May 22;68(21):1831-6.

PMID:
17515545
45.

Dynamic history of low-grade gliomas before and after temozolomide treatment.

Ricard D, Kaloshi G, Amiel-Benouaich A, Lejeune J, Marie Y, Mandonnet E, Kujas M, Mokhtari K, Taillibert S, Laigle-Donadey F, Carpentier AF, Omuro A, Capelle L, Duffau H, Cornu P, Guillevin R, Sanson M, Hoang-Xuan K, Delattre JY.

Ann Neurol. 2007 May;61(5):484-90.

PMID:
17469128
46.

Association of telomerase gene hTERT polymorphism and malignant gliomas.

Carpentier C, Lejeune J, Gros F, Everhard S, Marie Y, Kaloshi G, Laigle-Donadey F, Hoang-Xuan K, Delattre JY, Sanson M.

J Neurooncol. 2007 Sep;84(3):249-53. Epub 2007 Apr 5.

PMID:
17410334
47.

[Pattern of care of high-grade gliomas].

Laigle-Donadey F, Sanson M.

Rev Prat. 2006 Oct 31;56(16):1779-86. Review. French.

PMID:
17315503
48.

MGMT prognostic impact on glioblastoma is dependent on therapeutic modalities.

Crinière E, Kaloshi G, Laigle-Donadey F, Lejeune J, Auger N, Benouaich-Amiel A, Everhard S, Mokhtari K, Polivka M, Delattre JY, Hoang-Xuan K, Thillet J, Sanson M.

J Neurooncol. 2007 Jun;83(2):173-9. Epub 2007 Jan 12.

PMID:
17219056
49.

The 61 A/G EGF polymorphism is functional but is neither a prognostic marker nor a risk factor for glioblastoma.

Vauleon E, Auger N, Benouaich-Amiel A, Laigle-Donadey F, Kaloshi G, Lejeune J, Delattre JY, Thillet J, Sanson M.

Cancer Genet Cytogenet. 2007 Jan 1;172(1):33-7.

PMID:
17175377
50.

[Multiple gliomas: clinical studies and pathophysiological hypothesis].

Auré K, Laigle-Donadey F, Kaloshi G, Amiel-Benouaich A, Sanson M.

Rev Neurol (Paris). 2006 Sep;162(8-9):845-51. French.

PMID:
17028546

Supplemental Content

Loading ...
Support Center